慢性肾脏病 5D 期(关格)中医证素特征研究

注册号:

Registration number:

ITMCTR2025000025

最近更新日期:

Date of Last Refreshed on:

2025-01-07

注册时间:

Date of Registration:

2025-01-07

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

慢性肾脏病 5D 期(关格)中医证素特征研究

Public title:

Study on the characteristics of TCM syndrome elements in 5D stage of chronic kidney disease ( Guange )

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于证素辨识和状态可测原理的动静态中医临床评价方法学构建与示范研究中优势病种示范性研究:慢性肾脏病5D期(关格)中医证素特征研究及“法统病证”非药物疗法(灸疗)的个体化诊疗优选范例

Scientific title:

The demonstration study of dominant diseases in the construction and demonstration of dynamic and static TCM clinical evaluation methodology based on the principle of syndrome element identification and state measurability : the study of TCM syndrome element characteristics of chronic kidney disease stage 5D ( Guange ) and the optimal example of individualized diagnosis and treatment of non-drug therapy ( moxibustion ) of ' Fatong disease syndrom

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

乔雪

研究负责人:

邱模炎

Applicant:

Qiao Xue

Study leader:

Qiu Moyan

申请注册联系人电话:

Applicant telephone:

13269703258

研究负责人电话:

Study leader's telephone:

010-84739181

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bzs2410068_cacms@foxmail.com

研究负责人电子邮件:

Study leader's E-mail:

19233162363@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区中环南路6号北京中医药大学东校区

研究负责人通讯地址:

北京市朝阳区花家地街望京医院

Applicant address:

No.6 Zhonghuan South Road Chaoyang District Beijing East Campus of Beijing University of Chinese Medicine

Study leader's address:

Wangjing Hospital Huajiadi Street Chaoyang District Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院

Applicant's institution:

china academy of chinese medical sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

WJEC-KT-2024-071-P002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

中国中医科学院望京医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Wangjing Hospital of CACMS

伦理委员会批准日期:

Date of approved by ethic committee:

2024/10/17 0:00:00

伦理委员会联系人:

李浩

Contact Name of the ethic committee:

Li Hao

伦理委员会联系地址:

北京市朝阳区花家地街中国中医科学院望京医院

Contact Address of the ethic committee:

Wangjing Hospital of CACMS Huajiadi Street Chaoyang District Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-84739681

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wjyyec@126.com

研究实施负责(组长)单位:

中国中医科学院望京医院

Primary sponsor:

Wangjing Hospital of CACMS

研究实施负责(组长)单位地址:

北京市朝阳区花家地街望京医院

Primary sponsor's address:

Wangjing Hospital Huajiadi Street Chaoyang District Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院

具体地址:

北京市朝阳区花家地街望京医院

Institution
hospital:

Wangjing Hospital of CACMS

Address:

Wangjing Hospital Huajiadi Street Chaoyang District Beijing

经费或物资来源:

国家重点研发计划

Source(s) of funding:

national key research and development program

研究疾病:

慢性肾脏病5D期

研究疾病代码:

Target disease:

Chronic kidney disease stage 5D

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

队列研究

Cohort study

研究所处阶段:

Study phase:

其它

Others

研究目的:

通过临床调查,按照动态因素(地域、季节、单次血液透析前后)开展CKD 5D期血液透析患者中医证素特征研究。

Objectives of Study:

Through clinical investigation the characteristics of TCM syndromes in CKD 5D hemodialysis patients were studied according to dynamic factors ( region season before and after single hemodialysis ).

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)年龄≥18周岁; (2)符合终末期肾脏病的西医诊断标准; (3)规律血液透析≥3个月,透析频次2-4次/周; (4)意识清楚,无精神病史或人格障碍; (5)积极配合问卷调查,自愿参加并签署《知情同意书》。

Inclusion criteria

( 1 ) Age ≥ 18 years old ; ( 2 ) In line with the Western diagnostic criteria for end-stage renal disease ; ( 3 ) Regular hemodialysis ≥ 3 months dialysis frequency 2-4 times / week ; ( 4 ) clear consciousness no history of mental illness or personality disorder ; ( 5 ) Actively cooperate with the questionnaire survey voluntarily participate in and sign the ' informed consent '.

排除标准:

(1)预期寿命不足1年者; (2)合并严重心脑血管疾病、急性感染、恶性肿瘤、胃肠道与肝脏严重疾病、骨折者; (3)3个月内有手术者; (4)精神疾病、心理障碍等不能配合调查,或不签署知情同意书者。

Exclusion criteria:

( 1 ) Life expectancy less than 1 year ; ( 2 ) patients with severe cardiovascular and cerebrovascular diseases acute infections malignant tumors severe gastrointestinal and liver diseases and fractures ; ( 3 ) surgery within 3 months ; ( 4 ) mental illness mental disorders etc.can not cooperate with the investigation or do not sign informed consent.

研究实施时间:

Study execute time:

From 2023-11-01

To      2026-10-31

征募观察对象时间:

Recruiting time:

From 2025-03-20

To      2026-04-30

干预措施:

Interventions:

组别:

观察队列

样本量:

180

Group:

Observation cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

样本总量 Total sample size : 180

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

福建省

市(区县):

Country:

China

Province:

fujian province

City:

单位(医院):

福建中医药大学附属人民医院

单位级别:

三甲

Institution/hospital:

Fujian University of Traditional Chinese Medicine Affiliated People 's Hospital

Level of the institution:

tertiary level

国家:

中国

省(直辖市):

福建省

市(区县):

Country:

China

Province:

fujian province

City:

单位(医院):

福建中医药大学附属第三人民医院

单位级别:

三甲

Institution/hospital:

The Third People 's Hospital of Fujian University of Traditional Chinese Medicine

Level of the institution:

tertiary level

国家:

中国

省(直辖市):

福建省

市(区县):

Country:

China

Province:

fujian province

City:

单位(医院):

福建中医药大学附属第二人民医院

单位级别:

三甲

Institution/hospital:

The Second People 's Hospital of Fujian University of Traditional Chinese Medicine

Level of the institution:

tertiary level

测量指标:

Outcomes:

指标中文名:

慢性肾脏病5D期(关格)专病量表

指标类型:

主要指标

Outcome:

Chronic kidney disease stage 5D ( off ) special disease scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

non randomized

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年10月公开于数据库:1.中国知网(https://www.cnki.net/);2.PubMed(https://www.cnki.net/)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

October 2026 Open database: 1. China National Knowledge Network (https://www.cnki.net/); 2.PubMed (https://www.cnki.net/)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

(1)本研究应用电子化病例报告表(e-CRF)进行数据采集与管理,研究者填写电子病例报告表(e-CRF),保证数据记录及时、完整、准确、真实。 (2)研究者登录系统,进行数据录入,再由本中心质控员登录系统对每一项数据进行原始数据核对,对与原始病历不一致的结果值发出质疑,研究者针对质疑列表逐项核对原始数据,予以更正。以确保数据库的数据与原始记录表中数据一致。对标记完成后的数据做任何修改均需提供修改理由,并留有稽查痕迹。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

( 1 ) In this study the electronic case report form ( e-CRF ) was used for data collection and management. The researchers filled in the electronic case report form ( e-CRF ) to ensure that the data were recorded in a timely complete accurate and true manner. ( 2 ) The researcher logged in to the system for data entry and then the quality control system of the center logged in to check the original data for each data and questioned the result value inconsistent with the original medical record. The researcher checked the original data item by item for the query list and corrected it. To ensure that the data of the database is consistent with the data in the original record table. Any modification of the data after the completion of the markup needs to provide reasons for the modification and leave a trace of inspection.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统